Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

Erasca, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, SEPT. 08, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED ITS PARTICIPATION IN THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE BEING HELD AT THE NEW YORK MARRIOTT MARQUIS IN NEW YORK, NY.

ERASCA TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

SAN DIEGO, SEPT. 02, 2026 (GLOBE NEWSWIRE) -- JOHNSON FISTEL, PLLP IS INVESTIGATING POTENTIAL CLAIMS ON BEHALF OF CURRENT, LONG-TERM SHAREHOLDERS OF ERASCA, INC. (NASDAQ: ERAS) AGAINST CERTAIN OF ITS OFFICERS AND DIRECTORS FOR ALLEGED BREACHES OF FIDUCIARY DUTY.

LONG-TERM SHAREHOLDERS OF ERASCA, INC. (ERAS) ARE ENCOURAGED TO CONTACT JOHNSON FISTEL REGARDING POTENTIAL CLAIMS

DESIGNATION FOLLOWS ENCOURAGING PHASE 1 ACTIVITY ACROSS MULTIPLE TUMOR TYPES INCLUDING 2L+ KRAS G12X PANCREATIC CANCER THREE POTENTIALLY REGISTRATION-ENABLING TRIALS PLANNED ACROSS PANCREATIC AND LUNG CANCERS ADDITIONAL PHASE 1 MONOTHERAPY AND COMBINATION DATA EXPECTED IN H1 2027 SAN DIEGO, AUG. 24, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION (FTD) TO ERAS-0015 FOR THE TREATMENT OF PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA. ERAS-0015 IS AN ORAL, HIGHLY POTENT PAN-RAS MOLECULAR GLUE DESIGNED TO INHIBIT RAS SIGNALING WITH A POTENTIAL BEST-IN-CLASS PROFILE.

ERASCA GRANTED FDA FAST TRACK DESIGNATION FOR PAN-RAS MOLECULAR GLUE ERAS-0015 IN PATIENTS WITH METASTATIC PANCREATIC ADENOCARCINOMA

UPDATED ERAS-0015 DATA IN U.S. TRIAL HIGHLIGHTED COMPELLING MONOTHERAPY EFFICACY IN 2L+ KRAS G12X PDAC AND CONTINUED FAVORABLE TOLERABILITY, AS WELL AS FURTHER ADVANCEMENT OF PANITUMUMAB CRC COMBINATION

ERASCA REPORTS SECOND QUARTER 2026 BUSINESS UPDATES AND FINANCIAL RESULTS

LOS ANGELES, AUG. 10, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ: ERAS) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

ERASCA, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - ERAS

BRAGAR EAGEL & SQUIRE, P.C. LITIGATION PARTNERS BRANDON WALKER AND MELISSA FORTUNATO ENCOURAGE INVESTORS WHO SUFFERED LOSSES IN ERASCA (ERAS) TO CONTACT THEM DIRECTLY TO DISCUSS THEIR OPTIONS

ERASCA LEAD PLAINTIFF DEADLINE AUGUST 10TH: BRAGAR EAGEL & SQUIRE, P.C. REMINDS ERASCA, INC. (ERAS) INVESTORS WITH LARGE LOSSES TO CONTACT THE FIRM REGARDING THEIR RIGHTS

LOS ANGELES, AUG. 6, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ: ERAS) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 5, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ: ERAS) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ERASCA SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ERASCA AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX ENCOURAGES ERASCA, INC. (ERAS) INVESTORS WITH LOSSES TO CONTACT THE FIRM BEFORE AUGUST 10, 2026

NEW YORK, NEW YORK--(NEWSFILE CORP. - AUGUST 3, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ: ERAS) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ERASCA SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ERASCA AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX NOTIFIES ERASCA, INC. (ERAS) INVESTORS OF AN UPCOMING LEAD PLAINTIFF DEADLINE ON AUGUST 10, 2026

LOS ANGELES, AUG. 3, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ: ERAS) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

LOS ANGELES, JULY 31, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ:ERAS) FORVIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, NEW YORK--(NEWSFILE CORP. - JULY 27, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ: ERAS) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ERASCA SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ERASCA AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX URGES INVESTORS OF ERASCA, INC. (ERAS) WITH SIGNIFICANT LOSSES TO SEEK A LEADERSHIP ROLE BEFORE AUGUST 10, 2026

SAN DIEGO, CALIFORNIA--(NEWSFILE CORP. - JULY 27, 2026) - ROBBINS LLP REMINDS STOCKHOLDERS THAT A CLASS ACTION WAS FILED ON BEHALF OF ALL INVESTORS WHO PURCHASED OR OTHERWISE ACQUIRED ERASCA, INC. (NASDAQ: ERAS) SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026. ERASCA, INC., A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY, FOCUSES ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS.

ERAS STOCK DROP: IF YOU INCURRED SIGNIFICANT LOSSES IN ERASCA, INC., CONTACT ROBBINS LLP FOR INFORMATION ABOUT RECOVERING YOUR LOSSES

LOS ANGELES, JULY 27, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ: ERAS) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, NEW YORK--(NEWSFILE CORP. - JULY 24, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ: ERAS) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ERASCA SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ERASCA AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX REMINDS ERASCA, INC. (ERAS) INVESTORS SEEKING RECOVERY OF THE LEAD PLAINTIFF DEADLINE ON AUGUST 10, 2026

NEW YORK, NEW YORK--(NEWSFILE CORP. - JULY 20, 2026) - KAPLAN FOX & KILSHEIMER LLP ANNOUNCES THAT A CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ERASCA, INC. ("ERASCA" OR THE "COMPANY") (NASDAQ: ERAS) ON BEHALF OF INVESTORS THAT PURCHASED OR OTHERWISE ACQUIRED ERASCA SECURITIES BETWEEN JANUARY 14, 2025 AND APRIL 26, 2026 (THE "CLASS PERIOD"). CLICK HERE TO JOIN THE CASE IF YOU ARE AN INVESTOR IN ERASCA AND HAVE SUFFERED LOSSES, YOU MAY CLICK HERE TO CONTACT US.

KAPLAN FOX ENCOURAGES INVESTORS OF ERASCA, INC. (ERAS) WHO SUFFERED LOSSES TO CONTACT THE FIRM BEFORE AUGUST 10, 2026

SAN DIEGO, JULY 15, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THAT IT HAS CLOSED ITS PREVIOUSLY ANNOUNCED UPSIZED PUBLIC OFFERING OF 36,142,857 SHARES OF ITS COMMON STOCK, INCLUDING 4,714,285 SHARES SOLD PURSUANT TO THE UNDERWRITERS' FULL EXERCISE OF THEIR OPTION TO PURCHASE ADDITIONAL SHARES. THE SHARES OF COMMON STOCK WERE SOLD TO THE PUBLIC AT A PRICE OF $17.50 PER SHARE. THE GROSS PROCEEDS TO ERASCA FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, WERE APPROXIMATELY $632.5 MILLION. ALL OF THE SHARES OF COMMON STOCK SOLD IN THE PUBLIC OFFERING WERE SOLD BY ERASCA.

ERASCA ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK, INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

SAN DIEGO, JULY 13, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THE PRICING OF AN UPSIZED PUBLIC OFFERING OF 31,428,572 SHARES OF ITS COMMON STOCK. THE SHARES OF COMMON STOCK ARE BEING SOLD TO THE PUBLIC AT A PRICE OF $17.50 PER SHARE. ALL OF THE SHARES OF COMMON STOCK TO BE SOLD IN THE PUBLIC OFFERING ARE TO BE SOLD BY ERASCA. THE GROSS PROCEEDS TO ERASCA FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $550.0 MILLION. IN ADDITION, ERASCA HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 4,714,285 SHARES OF COMMON STOCK AT THE OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON JULY 15, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

ERASCA ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF COMMON STOCK

SAN DIEGO, JULY 13, 2026 (GLOBE NEWSWIRE) -- ERASCA, INC. (NASDAQ: ERAS), A CLINICAL-STAGE PRECISION ONCOLOGY COMPANY SINGULARLY FOCUSED ON DISCOVERING, DEVELOPING, AND COMMERCIALIZING THERAPIES FOR PATIENTS WITH RAS/MAPK PATHWAY-DRIVEN CANCERS, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL, SUBJECT TO MARKET AND OTHER CONDITIONS, $500.0 MILLION OF SHARES OF ITS COMMON STOCK IN A PROPOSED UNDERWRITTEN PUBLIC OFFERING. ALL OF THE SHARES OF COMMON STOCK TO BE SOLD IN THE PROPOSED OFFERING ARE BEING OFFERED BY ERASCA. IN ADDITION, ERASCA INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $75.0 MILLION OF SHARES OF ITS COMMON STOCK. THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED PUBLIC OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

ERASCA ANNOUNCES PROPOSED PUBLIC OFFERING OF $500 MILLION OF COMMON STOCK

AT RDE OF 32 MG QD, ENCOURAGING MONOTHERAPY RESPONSES WITH 57% UORR IN 2L+ KRAS G12X PANCREATIC CANCER IN U.S. TRIAL AND MEDIAN RELATIVE DOSE INTENSITY OF 100%

ERASCA ANNOUNCES UPDATED PRELIMINARY PHASE 1 DATA AND REGISTRATION-ENABLING PLANS FOR POTENTIALLY BEST-IN-CLASS PAN-RAS MOLECULAR GLUE ERAS-0015 IN KRAS-MUTANT SOLID TUMORS

LOS ANGELES, JULY 13, 2026 /PRNEWSWIRE/ -- THE DJS LAW GROUPREMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINSTERASCA, INC. ("ERASCA" OR "THE COMPANY") (NASDAQ: ERAS) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF ERAS DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

NEW YORK, JULY 08, 2026 (GLOBE NEWSWIRE) -- KIRBY MCINERNEY LLP REMINDS ERASCA, INC. (ERASCA OR THE COMPANY) (NASDAQ:ERAS) INVESTORS OF THE AUGUST 10, 2026 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A PENDING FEDERAL SECURITIES CLASS ACTION. COURTS DO NOT CONSIDER APPLICATIONS FILED AFTER THIS DEADLINE. THE LEAD PLAINTIFF OVERSEES THE LITIGATION ON BEHALF OF THE CLASS AND MAY INFLUENCE KEY DECISIONS, INCLUDING LITIGATION STRATEGY AND SETTLEMENT. COURTS REGULARLY APPOINT INDIVIDUAL INVESTORS AS LEAD PLAINTIFFS, NOT ONLY INSTITUTIONS. LEARN MORE ABOUT THE LEAD PLAINTIFF PROCESS AND ELIGIBILITY REQUIREMENTS HERE.

Erasca, Inc.

ERAS

Price

Financial Reports

No items found.

Press Releases

Erasca, Inc.

ERAS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ERAS